Vanguard Group’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-33,036
Closed -$704K – 4467
2024
Q1
$704K Buy
+33,036
New +$395K ﹤0.01% 3919
2021
Q2
– Sell
-36,394
Closed -$390K – 4455
2021
Q1
$390K Buy
36,394
+806
+2% +$9.42K ﹤0.01% 4169
2020
Q4
$418K Buy
+35,588
New +$447K ﹤0.01% 3992

Vanguard Group's FUSN Position: Q2 2024 in Review

Vanguard Group sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 33,036 shares — an estimated $704K sold.

Vanguard Group first reported a position in FUSN in Q4 2020 and held it in 3 quarters. The position peaked at $704K in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.

  • Vanguard Group reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 33,036 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $704K.
  • Vanguard Group first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2020 and held it in 3 quarters.
  • Vanguard Group's Fusion Pharmaceuticals Inc. Common Shares position peaked at $704K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.